LUCID DIAGNOSTICS INC (LUCD) Stock Price, Quote, News and Overview
NASDAQ:LUCD - Nasdaq - US54948X1090 - Common Stock - Currency: USD
LUCD Quote, Performance and Key Statistics
NASDAQ:LUCD (6/26/2025, 1:55:09 PM)
1.185
+0.03 (+2.16%)
The current stock price of LUCD is 1.185 USD. In the past month the price decreased by -23.68%. In the past year, price increased by 41.46%.
LUCD Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 27.98 | 232.67B | ||
| ISRG | INTUITIVE SURGICAL INC | 69.7 | 190.87B | ||
| BSX | BOSTON SCIENTIFIC CORP | 38.73 | 154.69B | ||
| SYK | STRYKER CORP | 31.08 | 148.85B | ||
| MDT | MEDTRONIC PLC | 15.69 | 110.66B | ||
| BDX | BECTON DICKINSON AND CO | 12.04 | 48.61B | ||
| EW | EDWARDS LIFESCIENCES CORP | 29.67 | 45.25B | ||
| IDXX | IDEXX LABORATORIES INC | 46.14 | 42.62B | ||
| RMD | RESMED INC | 28.26 | 37.62B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16.24 | 34.22B | ||
| DXCM | DEXCOM INC | 51.67 | 33.43B | ||
| STE | STERIS PLC | 25.53 | 23.43B |
Related stock screener links
About LUCD
Company Profile
Lucid Diagnostics, Inc. is a commercial-stage medical diagnostics technology company. The company is headquartered in New York City, New York. The company went IPO on 2021-10-14. The firm is focused on patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or simply reflux, that leads to esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma (EAC). The Company’s products include EsoGuard and EsoCheck. EsoGuard is a bisulfite-converted next generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in office procedures. The company consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone catheter from which a soft silicone balloon with textured ridges emerges to swab surface esophageal cells. The company is also developing EsoCure, is an Esophageal Ablation Device, which is a technology that allows a clinician to treat dysplastic BE.
Company Info
LUCID DIAGNOSTICS INC
360 Madison Avenue, 25th Floor
New York City NEW YORK US
Employees: 70
Phone: 12129494319
LUCID DIAGNOSTICS INC / LUCD FAQ
What is the stock price of LUCID DIAGNOSTICS INC today?
The current stock price of LUCD is 1.185 USD. The price increased by 2.16% in the last trading session.
What is the ticker symbol for LUCID DIAGNOSTICS INC stock?
The exchange symbol of LUCID DIAGNOSTICS INC is LUCD and it is listed on the Nasdaq exchange.
On which exchange is LUCD stock listed?
LUCD stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for LUCID DIAGNOSTICS INC stock?
12 analysts have analysed LUCD and the average price target is 3.87 USD. This implies a price increase of 226.37% is expected in the next year compared to the current price of 1.185. Check the LUCID DIAGNOSTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is LUCID DIAGNOSTICS INC worth?
LUCID DIAGNOSTICS INC (LUCD) has a market capitalization of 128.21M USD. This makes LUCD a Micro Cap stock.
How many employees does LUCID DIAGNOSTICS INC have?
LUCID DIAGNOSTICS INC (LUCD) currently has 70 employees.
What are the support and resistance levels for LUCID DIAGNOSTICS INC (LUCD) stock?
LUCID DIAGNOSTICS INC (LUCD) has a support level at 1.12 and a resistance level at 1.27. Check the full technical report for a detailed analysis of LUCD support and resistance levels.
Is LUCID DIAGNOSTICS INC (LUCD) expected to grow?
The Revenue of LUCID DIAGNOSTICS INC (LUCD) is expected to grow by 78.75% in the next year. Check the estimates tab for more information on the LUCD EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy LUCID DIAGNOSTICS INC (LUCD) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of LUCD, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of LUCD, evaluating the profitability, health, valuation and growth aspects
- LUCID DIAGNOSTICS INC (LUCD) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- LUCID DIAGNOSTICS INC (LUCD) Sales and EPS estimates to see what analysts future expectations are.
- LUCID DIAGNOSTICS INC (LUCD) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- LUCID DIAGNOSTICS INC (LUCD) Insider and Institutional Ownership to learn about the owners and their transactions.
- LUCID DIAGNOSTICS INC (LUCD) Stock Chart to make your own analysis
- LUCID DIAGNOSTICS INC (LUCD) Latest news and press-releases to stay up to date.
Does LUCID DIAGNOSTICS INC (LUCD) stock pay dividends?
LUCD does not pay a dividend.
When does LUCID DIAGNOSTICS INC (LUCD) report earnings?
LUCID DIAGNOSTICS INC (LUCD) will report earnings on 2025-08-11, before the market open.
What is the Price/Earnings (PE) ratio of LUCID DIAGNOSTICS INC (LUCD)?
LUCID DIAGNOSTICS INC (LUCD) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.18).
What is the Short Interest ratio of LUCID DIAGNOSTICS INC (LUCD) stock?
The outstanding short interest for LUCID DIAGNOSTICS INC (LUCD) is 1.53% of its float. Check the ownership tab for more information on the LUCD short interest.
LUCD Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to LUCD. When comparing the yearly performance of all stocks, LUCD turns out to be only a medium performer in the overall market: it outperformed 63.18% of all stocks.
LUCD Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to LUCD. LUCD may be in some trouble as it scores bad on both profitability and health.
LUCD Financial Highlights
Over the last trailing twelve months LUCD reported a non-GAAP Earnings per Share(EPS) of -1.18. The EPS increased by 3.28% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -216.3% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
LUCD Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to LUCD. The Buy consensus is the average rating of analysts ratings from 12 analysts.
For the next year, analysts expect an EPS growth of 35.96% and a revenue growth 78.75% for LUCD